AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2014
Jul 2, 2014
31580_dirs_2014-07-02_011cc7fa-7e4a-4a6f-b2a2-ef4c0d62135b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2014-07-01
Reporting Person: Schenkein David P (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-07-01 | Common Stock | S | 6500 | $46.52 | Disposed | 259772 | Indirect |
| 2014-07-01 | Common Stock | S | 6500 | $46.52 | Disposed | 180772 | Indirect |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $45.26 to $47.86. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F4: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.